Regeneron Wins $407 Million Antitrust Verdict Against Amgen (1)

Regeneron Pharmaceuticals secured a victory in an antitrust case that accused Amgen Inc. of anticompetitive bundling practices, as a jury awarded the company nearly $407 million in damages Thursday.

A jury in the US District Court for the District of Delaware found that Amgen violated antitrust and tort laws by using cross-therapeutic bundled rebates to prevent cholesterol-lowering drug Praluent from competing in the market.

The jury awarded Regeneron $136 million in compensatory damages and $271 million in punitive damages.

Regeneron sued in 2022, accusing Amgen of responding to a series of patent losses by pivoting to an illegal “bundling” scheme ...